Merck KGaA lowered its medium-term outlook for its healthcare and life-science segment due to China challenges and recent ...

Merck KGaA cut its mid-term sales growth target for its health-care division after a number of high-profile drug trial ...

Merck KGaA said its doors are open for more M&A, particularly for its manufacturing business, as the company tempers sales ...

Shares of Merck KGaA surged after the company confirmed its outlook for fiscal year 2024 and revisions to its mid-term sales ...

Clesrovimab (MK-1654), an Investigational RSV Monoclonal Antibody, Significantly Reduced Incidence of RSV Disease and ...

Clesrovimab scored on several endpoints, showing an ability to protect infants against the virus in their first RSV season.

Germany-based Merck KGaA has announced the launch of a new €290m ($317.6m) biosafety testing facility in Rockville, Maryland, ...

Jefferies analyst Brian Balchin maintained a Buy rating on Merck KGaA (0O14 – Research Report) today and set a price target of €180.00.

Merck said the Phase 2b/3 pivotal study evaluating a single dose of clesrovimab administered to healthy preterm and full-term infants met all prespecified endpoints, with consistent results through ...

This is the second SOD application center that Merck has established in Asia to meet the region’s high demand.

Merck & Co. hopes a new positive trial readout can return Keytruda to glory in head and neck cancer. | Merck & Co. hopes a ...

Merck (MRK) says it Capvaxive vaccine showed positive immune responses in a Phase 3 trial for adults at risk for pneumonia.